RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
about
Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveClinical Application of Targeted Next Generation Sequencing for Colorectal CancersPersonalized genomic analyses for cancer mutation discovery and interpretation.Circulating Cell-Free Tumour DNA in the Management of Cancer.Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centresPerformance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016).The State of the Art in Colorectal Cancer Molecular Biomarker Testing.Tumour heterogeneity: principles and practical consequences.Genetic mutations in human rectal cancers detected by targeted sequencing.Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.Liquid biopsy: unlocking the potentials of cell-free DNA.Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Pathological factors and prognosis of resected liver metastases of colorectal carcinoma: implications and proposal for a pathological reporting protocol.Molecular Biomarkers for the Evaluation of Colorectal Cancer.Primary combined neuroendocrine carcinoma (small-cell type) and squamous cell carcinoma of the colon.Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience.Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine
P2860
Q28070038-5FC02A9B-345D-4AC1-9AA9-4FE07FC8D55FQ28077199-AF1248FA-78FA-4510-B0CD-5B74A8B6396FQ35602861-969C09A0-1A19-4E8D-97CF-2457C9F099ADQ35814162-165119BE-ABC4-40D5-AE54-52B479B2B5B9Q35901968-C25E51D1-C392-4776-9166-36D7B88689A8Q36167042-EEEEE587-AC6E-4487-A484-EDEF5A3CA470Q36175288-046EBDC2-9E80-4606-9436-AF17EB2A4CE5Q36201032-5F0E5E18-B51E-4C9A-AEDD-CB0FFB67D5CCQ37282490-DA4325FD-4E90-4437-BA9D-BCA001282C05Q37600051-BF862E54-9475-4E72-BD2C-58A48917BC07Q38617495-4CCA7653-1B40-4BE5-AB22-4CFAEE17319AQ38659782-8AAFDA15-D344-4E19-BD27-1B1580764D71Q38707761-28A33420-8E46-4300-869A-4D44BC0515B2Q38724312-15277595-68E5-4152-B0E3-31B1D3EEDA14Q38842168-367EFBBD-A47A-421A-BEBA-75F3DBB916D0Q38989186-36363127-AB6F-45E3-B590-EA4521CB9CCEQ39023377-E44BF24F-A34F-4BA8-8279-BB4339BC9B4AQ39120801-E4F979CD-7AF0-4E9A-B4D7-6D652D61F5B8Q39279845-EC4D3215-A420-4E1A-8DE1-7178F77AD842Q39334444-F438FB4F-F652-4CE6-9914-6452D9817C5BQ40341349-683B3F59-948B-42DA-9068-BDBCC9DEBEBEQ41441029-3117CE5B-E5FB-4F81-B4CF-2C305795A656Q42183079-32609DD3-1945-46C2-8BD3-220835C216E7Q48146966-D78B8882-B295-4DDC-A892-49E01D97CF4DQ52794464-27565E34-D6FB-4FD9-8D4D-18F5C6B25B7FQ53407464-4F9916DF-7D99-4FA8-838E-62F5F401EAA4Q54958714-38ECD72C-F74E-45CE-8AF0-AFCECF0D5482Q55082628-CDCC1E4B-7DE7-4F00-BD1D-2C5888F3CDF4Q57162471-75978C35-AE0A-4C31-BB3F-5D052BB94585
P2860
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
RAS testing of colorectal carc ...... thology and Diagnostics Group.
@en
RAS testing of colorectal carc ...... thology and Diagnostics Group.
@nl
type
label
RAS testing of colorectal carc ...... thology and Diagnostics Group.
@en
RAS testing of colorectal carc ...... thology and Diagnostics Group.
@nl
prefLabel
RAS testing of colorectal carc ...... thology and Diagnostics Group.
@en
RAS testing of colorectal carc ...... thology and Diagnostics Group.
@nl
P2093
P2860
P50
P1476
RAS testing of colorectal carc ...... thology and Diagnostics Group.
@en
P2093
Association of Clinical Pathologists Molecular Pathology and Diagnostics Group
David Gonzalez
Manuel Salto-Tellez
Mohammad Ilyas
Newton A C S Wong
Philippe Taniere
Rachel Butler
Shaun V Walsh
P2860
P304
P356
10.1136/JCLINPATH-2014-202467
P407
P577
2014-09-01T00:00:00Z